MicroRNA 3529 (MIR3529)

MicroRNA 3529 (MIR3529) is a short, non-coding RNA molecule (20-24 nucleotides) classified as a microRNA (miRNA), which regulates gene expression at the post-transcriptional level by binding to target mRNA transcripts, leading to translation inhibition or mRNA destabilization[1][3]. MIR3529 is transcribed by RNA polymerase II, processed by Drosha and Dicer, and incorporated into the RNA-induced silencing complex (RISC) to mediate its regulatory effects[1][3]. Disease associations include infectious anterior uveitis and lung papillary adenocarcinoma[1]. Additionally, miR-3529-3p has been identified as inversely correlated with HIF-2α, VEGFR1, and VEGFR2 expression, and has been associated with reduced tumor shrinkage and poorer progression-free survival in patients receiving VEGFR-tyrosine kinase inhibitors[4]. No known drugs directly target microRNA 3529, and it is not considered a therapeutic receptor, enzyme, transporter, or traditional drug target[1]. Its primary significance lies in its function as a regulatory RNA and as a potential biomarker for cancer therapy response[4].

Other names

MIR3529hsa-mir-3529mir-3529